EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Karyopharm Therapeutics Inc. (KPTI) had EBIT Margin of -64.30% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$37.93M |
|
$-37.25M |
|
$1.05M |
|
$36.88M |
|
$62.32M |
|
$-24.39M |
|
$-12.82M |
|
$-37.21M |
|
$-37.21M |
|
$-37.25M |
|
$-37.25M |
|
$-37.25M |
|
$-37.25M |
|
$-24.39M |
|
$-21.71M |
|
8.62M |
|
8.62M |
|
$-4.32 |
|
$-4.32 |
|
| Balance Sheet Financials | |
$97.87M |
|
$0.24M |
|
$7.01M |
|
$104.88M |
|
$99.22M |
|
$152.25M |
|
$244.59M |
|
$343.81M |
|
$-238.93M |
|
$-238.93M |
|
$-238.93M |
|
8.65M |
|
| Cash Flow Statement Financials | |
$-57.68M |
|
$33.57M |
|
$0.36M |
|
$62.81M |
|
$39.08M |
|
$-23.74M |
|
$7.34M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.99 |
|
-- |
|
-- |
|
-1.76 |
|
-0.77 |
|
97.23% |
|
-64.30% |
|
|
EBIT Margin |
-64.30% |
-- |
|
-98.11% |
|
-98.22% |
|
$-57.68M |
|
-- |
|
-- |
|
-- |
|
0.36 |
|
0.21 |
|
1.15 |
|
78.14 |
|
15.59% |
|
15.59% |
|
-35.52% |
|
42.98% |
|
$-27.63 |
|
$-6.69 |
|
$-6.69 |
|